Eszopiclone + placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Insomnia
Conditions
Insomnia, Arthritis, Rheumatoid
Trial Timeline
Feb 1, 2004 → Nov 1, 2004
NCT ID
NCT00367965About Eszopiclone + placebo
Eszopiclone + placebo is a phase 3 stage product being developed by Sumitomo Pharma for Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT00367965. Target conditions include Insomnia, Arthritis, Rheumatoid.
What happened to similar drugs?
11 of 20 similar drugs in Insomnia were approved
Approved (11) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01102270 | Phase 1 | Completed |
| NCT00645944 | Pre-clinical | Completed |
| NCT00826111 | Approved | Completed |
| NCT00414037 | Approved | Terminated |
| NCT00386334 | Approved | Completed |
| NCT00833547 | Pre-clinical | Completed |
| NCT00392041 | Approved | Completed |
| NCT00365976 | Approved | Completed |
| NCT00555750 | Pre-clinical | Completed |
| NCT00374192 | Pre-clinical | Completed |
| NCT00368056 | Phase 3 | Completed |
| NCT00368160 | Phase 1 | Completed |
| NCT00367965 | Phase 3 | Completed |
| NCT00366093 | Phase 3 | Completed |
| NCT00352144 | Phase 3 | Completed |
| NCT00685269 | Phase 2 | Completed |
Competing Products
20 competing products in Insomnia